产品名称
Vimentin Recombinant Antibody - Rat IgG1 (Chimeric) - BSA and Azide free
抗体类型
Recombinant Chimeric Antibody
免疫原
Synthetic peptide within C-terminal human Vimentin.
靶点分子量
Predicted band size: 54 kDa
阳性对照
Human Appendix tissue, HeLa.
存放说明
Store at 2-8℃. Avoid freeze.
纯化方式
Protein A affinity purified.
功能
Vimentin (57 kDa) is the most ubiquituos intermediate filament protein and the first to be expressed during cell differentiation. All primitive cell types express vimentin but in most non-mesenchymal cells it is replaced by other intermediate filament proteins during differentiation. Vimentin is expressed in a wide variety of mesenchymal cell types: fibroblasts, endothelial cells etc., and in a number of other cell types derived from mesoderm, e.g., mesothelium and ovarian granulosa cells. Vimentin is present in many different neoplasms but is particulary expressed in those originated from mesenchymal cells. Sarcomas e.g., fibrosarcoma, malignt fibrous histiocytoma, angiosarcoma, and leio- and rhabdomyosarcoma, as well as lymphomas, malignant melanoma and schwannoma, are virtually always vimentin positive. Mesoderm derived carcinomas like renal cell carcinoma, adrenal cortical carcinoma and adenocarcinomas from endometrium and ovary usually express vimentin. Also thyroid carcinomas are vimentin positive. Any low differentiated or sarcomatoid carcinoma may express some vimentin. Vimentin is frequently included in the so-called primary panel (together with CD45, cytokeratin, and S-100 protein): Intense staining reaction for vimentin without coexpression of other intermediate filament proteins is strongly suggestive of a mesenchymal tumour or a malignant melanoma. However, in biopsies representing only a sarcomatoid part of renal cell carcinoma a.o. a strong positivity for vimentin without cytokeratin expression may be seen. Tumours like lymphomas and seminomas have the same intermediate filament profile, but the vimentin expression is usually weaker.
背景文献
1. Ridge KM et al. Roles of vimentin in health and disease. Genes Dev. 2022 Apr
2. Kuburich NA et al. Vimentin and cytokeratin: Good alone, bad together. Semin Cancer Biol. 2022 Nov
别名
CTRCT30 antibody
Epididymis luminal protein 113 antibody
FLJ36605 antibody
HEL113 antibody
VIM antibody
VIME_HUMAN antibody
Vimentin antibody
-
This data was developed using HA601564, the same antibody clone in a different buffer formulation.
Application: Immunohistochemistry (IHC-P)
Species: Human
Tissue: Appendix
Sample: Paraffin-embedded section
Antigen retrieval: Heat-mediated, Tris-EDTA buffer (pH 9.0), 20 minutes at 95℃.
Wash buffer: 1× TBST
Endogenous peroxidase blocking: 3% H₂O₂, 10 minutes at room temperature.
Blocking: 1% BSA + 10% normal goat serum, 10 minutes at room temperature.
Primary antibody: HA601564, 1/1,000, 1 hour at room temperature.
Secondary antibody: HA1023, 30 minutes at room temperature.
-
This data was developed using HA601564, the same antibody clone in a different buffer formulation.
Application: Immunocytochemistry (IF-cell)
Species: Human
Sample: HeLa (Human cervix adenocarcinoma epithelial cell)
Fixation: 4% Paraformaldehyde, 15 minutes at room temperature.
Permeabilization: 0.1% Triton X-100, 15 minutes at room temperature.
Blocking: 1% BSA + 10% normal goat serum, 1 hour at room temperature.
Antibody dilution buffer: 1% BSA in PBST.
Primary antibody: HA601564, 1/100, overnight at 4℃.
Secondary antibody: Goat Anti-Rat IgG (iFluor™ 488, HA1133), 45 minutes at room temperature.
Counterstain: Beta tubulin (ET1602-4, Red), 1/100, overnight at 4℃. The nuclear counterstain was DAPI (Blue).
请注意: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"